WO2006095906A1 - 複素環式化合物を有効成分とする免疫抑制剤及び抗腫瘍剤 - Google Patents
複素環式化合物を有効成分とする免疫抑制剤及び抗腫瘍剤 Download PDFInfo
- Publication number
- WO2006095906A1 WO2006095906A1 PCT/JP2006/304937 JP2006304937W WO2006095906A1 WO 2006095906 A1 WO2006095906 A1 WO 2006095906A1 JP 2006304937 W JP2006304937 W JP 2006304937W WO 2006095906 A1 WO2006095906 A1 WO 2006095906A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- triazine
- morpholino
- difluoromethylbenzimidazole
- dimethylmorpholino
- pyrimidine
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title claims abstract description 32
- 239000003018 immunosuppressive agent Substances 0.000 title claims abstract description 22
- 239000004480 active ingredient Substances 0.000 title claims abstract description 11
- 229940125721 immunosuppressive agent Drugs 0.000 title claims abstract description 9
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 64
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- -1 aromatic carbonyl Chemical group 0.000 claims description 245
- 229910052739 hydrogen Inorganic materials 0.000 claims description 108
- 125000000217 alkyl group Chemical group 0.000 claims description 65
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 52
- 229910052757 nitrogen Inorganic materials 0.000 claims description 46
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 43
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims description 36
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 33
- 201000010099 disease Diseases 0.000 claims description 32
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 29
- 125000003277 amino group Chemical group 0.000 claims description 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 24
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 24
- 125000003545 alkoxy group Chemical group 0.000 claims description 23
- 125000001424 substituent group Chemical group 0.000 claims description 22
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 21
- 208000023275 Autoimmune disease Diseases 0.000 claims description 16
- 125000005188 oxoalkyl group Chemical group 0.000 claims description 16
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 16
- FIDRAVVQGKNYQK-UHFFFAOYSA-N 1,2,3,4-tetrahydrotriazine Chemical compound C1NNNC=C1 FIDRAVVQGKNYQK-UHFFFAOYSA-N 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 15
- HGVNLRPZOWWDKD-UHFFFAOYSA-N ZSTK-474 Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCOCC1 HGVNLRPZOWWDKD-UHFFFAOYSA-N 0.000 claims description 14
- 125000003282 alkyl amino group Chemical group 0.000 claims description 14
- 230000000172 allergic effect Effects 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 13
- 208000006673 asthma Diseases 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 13
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 13
- 208000027866 inflammatory disease Diseases 0.000 claims description 13
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 13
- 208000010668 atopic eczema Diseases 0.000 claims description 12
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 10
- 241001481833 Coryphaena hippurus Species 0.000 claims description 10
- 208000011231 Crohn disease Diseases 0.000 claims description 10
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 10
- 201000004681 Psoriasis Diseases 0.000 claims description 10
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 10
- 208000017520 skin disease Diseases 0.000 claims description 10
- 208000011580 syndromic disease Diseases 0.000 claims description 10
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 9
- 201000008937 atopic dermatitis Diseases 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 9
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 7
- 230000001861 immunosuppressant effect Effects 0.000 claims description 7
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 7
- 230000002757 inflammatory effect Effects 0.000 claims description 6
- 125000004193 piperazinyl group Chemical group 0.000 claims description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 5
- XMFYMWXCIWIHAC-UHFFFAOYSA-N n,n-dimethylpiperazine-1-carboxamide Chemical compound CN(C)C(=O)N1CCNCC1 XMFYMWXCIWIHAC-UHFFFAOYSA-N 0.000 claims description 5
- 150000003230 pyrimidines Chemical class 0.000 claims description 5
- XLEIEOBSODBREI-UHFFFAOYSA-N 2-(difluoromethyl)-1-[4-[2-(hydroxymethyl)pyrrolidin-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]benzimidazol-4-ol Chemical compound OCC1CCCN1C1=NC(N2CCOCC2)=NC(N2C3=CC=CC(O)=C3N=C2C(F)F)=N1 XLEIEOBSODBREI-UHFFFAOYSA-N 0.000 claims description 4
- LTJNVKGEQOAUFC-IUCAKERBSA-N C[C@@H]1OCCN([C@H]1C)C1=NC=CC=N1 Chemical compound C[C@@H]1OCCN([C@H]1C)C1=NC=CC=N1 LTJNVKGEQOAUFC-IUCAKERBSA-N 0.000 claims description 4
- 230000001506 immunosuppresive effect Effects 0.000 claims description 4
- MUHMAIJBIHYGOQ-GJZGRUSLSA-N (2s,3s)-4-[4-(benzimidazol-1-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]-2,3-dimethylmorpholine Chemical compound C[C@H]1[C@H](C)OCCN1C1=NC(N2CCOCC2)=NC(N2C3=CC=CC=C3N=C2)=N1 MUHMAIJBIHYGOQ-GJZGRUSLSA-N 0.000 claims description 3
- UPLOSRJEEIWXGW-UHFFFAOYSA-N 2-(difluoromethyl)-1-[4-(2,2-dimethylmorpholin-4-yl)-6-morpholin-4-ylpyrimidin-2-yl]benzimidazol-4-ol Chemical compound C1COC(C)(C)CN1C1=CC(N2CCOCC2)=NC(N2C3=CC=CC(O)=C3N=C2C(F)F)=N1 UPLOSRJEEIWXGW-UHFFFAOYSA-N 0.000 claims description 3
- JEDLLKZKXSMSBV-UHFFFAOYSA-N 4-[4-(2-methylbenzimidazol-1-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]morpholine Chemical compound CC1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCOCC1 JEDLLKZKXSMSBV-UHFFFAOYSA-N 0.000 claims description 3
- MLLFCHTZCVFTNS-UHFFFAOYSA-N CC1(OCCN(C1)C1=NC=CC=N1)C Chemical compound CC1(OCCN(C1)C1=NC=CC=N1)C MLLFCHTZCVFTNS-UHFFFAOYSA-N 0.000 claims description 3
- 206010062016 Immunosuppression Diseases 0.000 claims description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 3
- KAQLRVBIQLPPOH-UHFFFAOYSA-N [4-[2-[2-(difluoromethyl)benzimidazol-1-yl]-6-(2,2-dimethylmorpholin-4-yl)pyrimidin-4-yl]piperazin-1-yl]-(furan-2-yl)methanone Chemical compound C1COC(C)(C)CN1C1=CC(N2CCN(CC2)C(=O)C=2OC=CC=2)=NC(N2C3=CC=CC=C3N=C2C(F)F)=N1 KAQLRVBIQLPPOH-UHFFFAOYSA-N 0.000 claims description 3
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims description 2
- VEGLQCYQXRHREW-UHFFFAOYSA-N 1-(4,6-dimorpholin-4-ylpyrimidin-2-yl)benzimidazol-2-amine Chemical compound NC1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=CC=1N1CCOCC1 VEGLQCYQXRHREW-UHFFFAOYSA-N 0.000 claims description 2
- DDXVHJRHJCTDAG-UHFFFAOYSA-N 2,2-dimethyl-4-(1,3,5-triazin-2-yl)morpholine Chemical compound CC1(OCCN(C1)C1=NC=NC=N1)C DDXVHJRHJCTDAG-UHFFFAOYSA-N 0.000 claims description 2
- AVNYNMGNBKQTSQ-UHFFFAOYSA-N 2,6-dimethyl-4-pyrimidin-2-ylmorpholine Chemical compound C1C(C)OC(C)CN1C1=NC=CC=N1 AVNYNMGNBKQTSQ-UHFFFAOYSA-N 0.000 claims description 2
- PURNIHSRWGYONZ-UHFFFAOYSA-N 2-(difluoromethyl)-1h-benzimidazole Chemical compound C1=CC=C2NC(C(F)F)=NC2=C1 PURNIHSRWGYONZ-UHFFFAOYSA-N 0.000 claims description 2
- MGOSYGOVJLPLGX-OLZOCXBDSA-N 2-(difluoromethyl)-3-[4-[(2s,3r)-2,3-dimethylmorpholin-4-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]benzimidazol-5-amine Chemical compound C[C@@H]1[C@H](C)OCCN1C1=NC(N2CCOCC2)=NC(N2C3=CC(N)=CC=C3N=C2C(F)F)=N1 MGOSYGOVJLPLGX-OLZOCXBDSA-N 0.000 claims description 2
- RHRQKRJGORZWEV-UHFFFAOYSA-N 4-(1,3,5-triazin-2-yl)morpholine Chemical compound C1COCCN1C1=NC=NC=N1 RHRQKRJGORZWEV-UHFFFAOYSA-N 0.000 claims description 2
- JEGZWSARFPBOSR-UHFFFAOYSA-N 4-[4-[2-(difluoromethyl)-4-methylbenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]morpholine Chemical compound FC(F)C1=NC=2C(C)=CC=CC=2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCOCC1 JEGZWSARFPBOSR-UHFFFAOYSA-N 0.000 claims description 2
- XRQHORGXFBDJLP-UHFFFAOYSA-N 4-[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]piperazine-2,6-dione Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CC(=O)NC(=O)C1 XRQHORGXFBDJLP-UHFFFAOYSA-N 0.000 claims description 2
- OGBPVMMFHBOWQT-UHFFFAOYSA-N 4-[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-piperazin-1-yl-1,3,5-triazin-2-yl]morpholine Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCNCC2)=NC=1N1CCOCC1 OGBPVMMFHBOWQT-UHFFFAOYSA-N 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- QIKMZLIWHHGXQS-UHFFFAOYSA-N [1-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)benzimidazol-2-yl]methanol Chemical compound OCC1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCOCC1 QIKMZLIWHHGXQS-UHFFFAOYSA-N 0.000 claims description 2
- HENAWEKUKGPUTD-UHFFFAOYSA-N [4-[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]piperazin-1-yl]-(furan-2-yl)methanone Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 HENAWEKUKGPUTD-UHFFFAOYSA-N 0.000 claims description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 2
- IONKDTVJULDEBM-YUMQZZPRSA-N (2S,3S)-2,3-dimethyl-4-(1,3,5-triazin-2-yl)morpholine Chemical compound C[C@@H]1OCCN([C@H]1C)C1=NC=NC=N1 IONKDTVJULDEBM-YUMQZZPRSA-N 0.000 claims 3
- DMRWFMNXMGXRCN-UHFFFAOYSA-N 2-(difluoromethyl)-1h-benzimidazol-4-ol Chemical compound OC1=CC=CC2=C1N=C(C(F)F)N2 DMRWFMNXMGXRCN-UHFFFAOYSA-N 0.000 claims 3
- 241000271025 Vipera Species 0.000 claims 2
- FUDUGCQPHSNIAB-UHFFFAOYSA-N [4-[2-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-ylpyrimidin-4-yl]piperazin-1-yl]-(furan-2-yl)methanone Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=CC=1N(CC1)CCN1C(=O)C1=CC=CO1 FUDUGCQPHSNIAB-UHFFFAOYSA-N 0.000 claims 2
- KQAPBKZZOQWPCJ-UHFFFAOYSA-N furan-2-yl-[1-[2-[2-(hydroxymethyl)benzimidazol-1-yl]-6-morpholin-4-ylpyrimidin-4-yl]piperazin-2-yl]methanone Chemical compound OCC1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=CC=1N1CCNCC1C(=O)C1=CC=CO1 KQAPBKZZOQWPCJ-UHFFFAOYSA-N 0.000 claims 2
- LTJFPCBECZHXNS-WDSKDSINSA-N (2s,3s)-2,3-dimethylmorpholine Chemical compound C[C@@H]1NCCO[C@H]1C LTJFPCBECZHXNS-WDSKDSINSA-N 0.000 claims 1
- BPOSAPCWBGLDLZ-UHFFFAOYSA-N 1-[4-[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-(2,2-dimethylmorpholin-4-yl)-1,3,5-triazin-2-yl]piperazin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCN1C1=NC(N2CC(C)(C)OCC2)=NC(N2C3=CC=CC=C3N=C2C(F)F)=N1 BPOSAPCWBGLDLZ-UHFFFAOYSA-N 0.000 claims 1
- AXERSVBVRXPBCB-UHFFFAOYSA-N 2-(difluoromethyl)-1-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)benzimidazol-5-ol Chemical compound FC(F)C1=NC2=CC(O)=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCOCC1 AXERSVBVRXPBCB-UHFFFAOYSA-N 0.000 claims 1
- TZONKADGGKNWMG-UHFFFAOYSA-N 2-(difluoromethyl)-1-[4-[2-(hydroxymethyl)pyrrolidin-1-yl]-6-morpholin-4-ylpyrimidin-2-yl]benzimidazol-4-ol Chemical compound OCC1CCCN1C1=CC(N2CCOCC2)=NC(N2C3=CC=CC(O)=C3N=C2C(F)F)=N1 TZONKADGGKNWMG-UHFFFAOYSA-N 0.000 claims 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- MEXVSXLSOCQSJM-UHFFFAOYSA-N 4-[2-(2-methylbenzimidazol-1-yl)-6-morpholin-4-ylpyrimidin-4-yl]morpholine Chemical compound CC1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=CC=1N1CCOCC1 MEXVSXLSOCQSJM-UHFFFAOYSA-N 0.000 claims 1
- VFKRWPOUWLGESW-UHFFFAOYSA-N 4-[2-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-morpholin-4-ylpyrimidin-4-yl]-2,6-dimethylmorpholine Chemical compound FC(F)C1=NC=2C(OC)=CC=CC=2N1C(N=1)=NC(N2CCOCC2)=CC=1N1CC(C)OC(C)C1 VFKRWPOUWLGESW-UHFFFAOYSA-N 0.000 claims 1
- XNDLLBIIDRBACS-UHFFFAOYSA-N 4-[2-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-ylpyrimidin-4-yl]piperazin-2-one Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=CC=1N1CCNC(=O)C1 XNDLLBIIDRBACS-UHFFFAOYSA-N 0.000 claims 1
- ICJIDIDWCLRKID-UHFFFAOYSA-N 4-[2-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-ylpyrimidin-4-yl]piperazine-1-carbaldehyde Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=CC=1N1CCN(C=O)CC1 ICJIDIDWCLRKID-UHFFFAOYSA-N 0.000 claims 1
- QWZGLKXCVJIMDU-UHFFFAOYSA-N 4-[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]piperazin-2-one Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCNC(=O)C1 QWZGLKXCVJIMDU-UHFFFAOYSA-N 0.000 claims 1
- MQTNPNWSIRGVDX-UHFFFAOYSA-N 4-[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-piperidin-1-yl-1,3,5-triazin-2-yl]morpholine Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCCCC2)=NC=1N1CCOCC1 MQTNPNWSIRGVDX-UHFFFAOYSA-N 0.000 claims 1
- JSYOATZRHMUSLX-UHFFFAOYSA-N 4-chloro-2-(difluoromethyl)-1-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)benzimidazol-5-ol Chemical compound FC(F)C1=NC2=C(Cl)C(O)=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCOCC1 JSYOATZRHMUSLX-UHFFFAOYSA-N 0.000 claims 1
- IKGQXXTWGSIDDR-UHFFFAOYSA-N 7-chloro-2-(difluoromethyl)-3-[4-(2,2-dimethylmorpholin-4-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]benzimidazol-5-amine Chemical compound C1COC(C)(C)CN1C1=NC(N2CCOCC2)=NC(N2C3=CC(N)=CC(Cl)=C3N=C2C(F)F)=N1 IKGQXXTWGSIDDR-UHFFFAOYSA-N 0.000 claims 1
- 101100443238 Caenorhabditis elegans dif-1 gene Chemical group 0.000 claims 1
- FHFUWIIHHUCPGF-UHFFFAOYSA-N [1-(4,6-dimorpholin-4-ylpyrimidin-2-yl)benzimidazol-2-yl]methanol Chemical compound OCC1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=CC=1N1CCOCC1 FHFUWIIHHUCPGF-UHFFFAOYSA-N 0.000 claims 1
- DQTTYRXGLOLFEG-UHFFFAOYSA-N [4-[2-[4-amino-2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-ylpyrimidin-4-yl]piperazin-1-yl]-(furan-2-yl)methanone Chemical class FC(F)C1=NC=2C(N)=CC=CC=2N1C(N=1)=NC(N2CCOCC2)=CC=1N(CC1)CCN1C(=O)C1=CC=CO1 DQTTYRXGLOLFEG-UHFFFAOYSA-N 0.000 claims 1
- VYYLMWXXEPEUQD-UHFFFAOYSA-N [4-[4-[2-(difluoromethyl)-4-hydroxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]piperazin-1-yl]-(furan-2-yl)methanone Chemical compound FC(F)C1=NC=2C(O)=CC=CC=2N1C(N=1)=NC(N2CCOCC2)=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 VYYLMWXXEPEUQD-UHFFFAOYSA-N 0.000 claims 1
- PFUAJSJHXJSIAX-UHFFFAOYSA-N [4-[4-[4-amino-2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]piperazin-1-yl]-(furan-2-yl)methanone Chemical compound FC(F)C1=NC=2C(N)=CC=CC=2N1C(N=1)=NC(N2CCOCC2)=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 PFUAJSJHXJSIAX-UHFFFAOYSA-N 0.000 claims 1
- BFAKENXZKHGIGE-UHFFFAOYSA-N bis(2,3,5,6-tetrafluoro-4-iodophenyl)diazene Chemical compound FC1=C(C(=C(C(=C1F)I)F)F)N=NC1=C(C(=C(C(=C1F)F)I)F)F BFAKENXZKHGIGE-UHFFFAOYSA-N 0.000 claims 1
- JDZLOJYSBBLXQD-UHFFFAOYSA-N difluoromethylbenzene Chemical compound FC(F)C1=CC=CC=C1 JDZLOJYSBBLXQD-UHFFFAOYSA-N 0.000 claims 1
- GLRKSUMVISCRFE-UHFFFAOYSA-N furan-2-yl-[1-[4-[2-(hydroxymethyl)benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]piperazin-2-yl]methanone Chemical compound OCC1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCNCC1C(=O)C1=CC=CO1 GLRKSUMVISCRFE-UHFFFAOYSA-N 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000008629 immune suppression Effects 0.000 claims 1
- IVXQBCUBSIPQGU-UHFFFAOYSA-N piperazine-1-carboxamide Chemical compound NC(=O)N1CCNCC1 IVXQBCUBSIPQGU-UHFFFAOYSA-N 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 229940110851 tolazine Drugs 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 57
- 210000004027 cell Anatomy 0.000 description 50
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- 238000004519 manufacturing process Methods 0.000 description 36
- 238000002844 melting Methods 0.000 description 34
- 230000008018 melting Effects 0.000 description 34
- 238000005481 NMR spectroscopy Methods 0.000 description 31
- 229940125782 compound 2 Drugs 0.000 description 27
- 108091007960 PI3Ks Proteins 0.000 description 23
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 23
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 22
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- 239000000126 substance Substances 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 206010025323 Lymphomas Diseases 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 206010040047 Sepsis Diseases 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 11
- 229940125904 compound 1 Drugs 0.000 description 11
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical class C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 description 10
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 10
- 229940126214 compound 3 Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 10
- 229920006008 lipopolysaccharide Polymers 0.000 description 10
- 150000003905 phosphatidylinositols Chemical class 0.000 description 10
- 238000002054 transplantation Methods 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000007995 HEPES buffer Substances 0.000 description 9
- 208000028004 allergic respiratory disease Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000012091 fetal bovine serum Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 208000011623 Obstructive Lung disease Diseases 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 201000005787 hematologic cancer Diseases 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 208000009386 Experimental Arthritis Diseases 0.000 description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 7
- 208000034578 Multiple myelomas Diseases 0.000 description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 description 7
- 239000012980 RPMI-1640 medium Substances 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 239000004305 biphenyl Substances 0.000 description 7
- 235000010290 biphenyl Nutrition 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 7
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 7
- VGUZYUWJHVWNLB-UHFFFAOYSA-N 4-[4-[2-(difluoromethyl)-6-ethoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]morpholine Chemical compound C12=CC(OCC)=CC=C2N=C(C(F)F)N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCOCC1 VGUZYUWJHVWNLB-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 206010000830 Acute leukaemia Diseases 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 206010039710 Scleroderma Diseases 0.000 description 6
- 206010003246 arthritis Diseases 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 125000006267 biphenyl group Chemical group 0.000 description 6
- 208000024207 chronic leukemia Diseases 0.000 description 6
- 239000002131 composite material Substances 0.000 description 6
- 238000000354 decomposition reaction Methods 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 6
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 6
- 208000026278 immune system disease Diseases 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 210000002437 synoviocyte Anatomy 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 239000012828 PI3K inhibitor Substances 0.000 description 5
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 description 5
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- IAJLTMBBAVVMQO-UHFFFAOYSA-N 1h-benzimidazol-2-ylmethanol Chemical compound C1=CC=C2NC(CO)=NC2=C1 IAJLTMBBAVVMQO-UHFFFAOYSA-N 0.000 description 4
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 description 4
- 108010029697 CD40 Ligand Proteins 0.000 description 4
- 102100032937 CD40 ligand Human genes 0.000 description 4
- 108010062580 Concanavalin A Proteins 0.000 description 4
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 4
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- REAYFGLASQTHKB-UHFFFAOYSA-N [2-[3-(1H-pyrazol-4-yl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound N1N=CC(=C1)C=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 REAYFGLASQTHKB-UHFFFAOYSA-N 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 229940063774 carbon dioxide 5 % Drugs 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000010322 bone marrow transplantation Methods 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 229940126086 compound 21 Drugs 0.000 description 3
- 229940126208 compound 22 Drugs 0.000 description 3
- 229940125961 compound 24 Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 208000025113 myeloid leukemia Diseases 0.000 description 3
- VQSRKMNBWMHJKY-YTEVENLXSA-N n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-methoxypyrazine-2-carboxamide Chemical compound C1=NC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@@]23[C@@H](CN(C2)C=2N=CC(F)=CN=2)CSC(N)=N3)=C1 VQSRKMNBWMHJKY-YTEVENLXSA-N 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000005222 synovial tissue Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- AVINCSKSPOENJS-UHFFFAOYSA-N 2-(difluoromethyl)-1-(4,6-dimorpholin-4-ylpyrimidin-2-yl)benzimidazol-4-ol Chemical compound FC(F)C1=NC=2C(O)=CC=CC=2N1C(N=1)=NC(N2CCOCC2)=CC=1N1CCOCC1 AVINCSKSPOENJS-UHFFFAOYSA-N 0.000 description 2
- YRSOIOVGDHRVKD-UHFFFAOYSA-N 2-(difluoromethyl)-1-[4-(3,3-dimethylmorpholin-4-yl)-6-morpholin-4-ylpyrimidin-2-yl]benzimidazol-4-ol Chemical compound CC1(C)COCCN1C1=CC(N2CCOCC2)=NC(N2C3=CC=CC(O)=C3N=C2C(F)F)=N1 YRSOIOVGDHRVKD-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 2
- TZVYUJVJFOSDAY-UHFFFAOYSA-N 4-[2-[2-(difluoromethyl)-4-ethoxybenzimidazol-1-yl]-6-morpholin-4-ylpyrimidin-4-yl]-2,2-dimethylmorpholine Chemical compound FC(F)C1=NC=2C(OCC)=CC=CC=2N1C(N=1)=NC(N2CCOCC2)=CC=1N1CCOC(C)(C)C1 TZVYUJVJFOSDAY-UHFFFAOYSA-N 0.000 description 2
- ZAEMYFFMEAIBNS-UHFFFAOYSA-N 4-[4-[2-(difluoromethyl)-5-methoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]morpholine Chemical compound FC(F)C1=NC2=CC(OC)=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCOCC1 ZAEMYFFMEAIBNS-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- ISMDILRWKSYCOD-GNKBHMEESA-N C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O Chemical compound C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O ISMDILRWKSYCOD-GNKBHMEESA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241001247437 Cerbera odollam Species 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 229940126639 Compound 33 Drugs 0.000 description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 206010058339 Splenitis Diseases 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940127573 compound 38 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000001177 diphosphate Substances 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000007886 mutagenicity Effects 0.000 description 2
- 231100000299 mutagenicity Toxicity 0.000 description 2
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 2
- 208000008423 pleurisy Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 2
- 229960003111 prochlorperazine Drugs 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000013076 target substance Substances 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 206010043778 thyroiditis Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- KGTHGFMLGOGSDL-PHIMTYICSA-N (2r,6s)-4-[6-chloro-2-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]pyrimidin-4-yl]-2,6-dimethylmorpholine Chemical compound FC(F)C1=NC=2C(OC)=CC=CC=2N1C(N=1)=NC(Cl)=CC=1N1C[C@H](C)O[C@H](C)C1 KGTHGFMLGOGSDL-PHIMTYICSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- AVNYNMGNBKQTSQ-DTORHVGOSA-N (2s,6r)-2,6-dimethyl-4-pyrimidin-2-ylmorpholine Chemical compound C1[C@@H](C)O[C@@H](C)CN1C1=NC=CC=N1 AVNYNMGNBKQTSQ-DTORHVGOSA-N 0.000 description 1
- SMXOHNCXXITEJT-UHFFFAOYSA-N 1,3,5-triazine Chemical group C1=NC=NC=N1.C1=NC=NC=N1 SMXOHNCXXITEJT-UHFFFAOYSA-N 0.000 description 1
- PZOIYBFCTWHGRM-UHFFFAOYSA-N 1-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)benzimidazol-2-amine Chemical compound NC1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCOCC1 PZOIYBFCTWHGRM-UHFFFAOYSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- PYBWUZKLMWRYKH-UHFFFAOYSA-N 1-[4,6-bis(2,6-dimethylmorpholin-4-yl)pyrimidin-2-yl]-2-(difluoromethyl)benzimidazol-5-amine Chemical compound C1C(C)OC(C)CN1C1=CC(N2CC(C)OC(C)C2)=NC(N2C3=CC=C(N)C=C3N=C2C(F)F)=N1 PYBWUZKLMWRYKH-UHFFFAOYSA-N 0.000 description 1
- YKAXMQCMDULQHP-UHFFFAOYSA-N 1-[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]-1,4-diazepan-5-one Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCNC(=O)CC1 YKAXMQCMDULQHP-UHFFFAOYSA-N 0.000 description 1
- AZCSZUNXDTWWAD-UHFFFAOYSA-N 1-[4-[2-[2-(difluoromethyl)-4-hydroxybenzimidazol-1-yl]-6-morpholin-4-ylpyrimidin-4-yl]piperazin-1-yl]-2-methoxyethanone Chemical compound C1CN(C(=O)COC)CCN1C1=CC(N2CCOCC2)=NC(N2C3=CC=CC(O)=C3N=C2C(F)F)=N1 AZCSZUNXDTWWAD-UHFFFAOYSA-N 0.000 description 1
- LCWNJRUKTAQWHZ-UHFFFAOYSA-N 1-[4-[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]piperazin-1-yl]-2-methoxyethanone Chemical compound C1CN(C(=O)COC)CCN1C1=NC(N2CCOCC2)=NC(N2C3=CC=CC=C3N=C2C(F)F)=N1 LCWNJRUKTAQWHZ-UHFFFAOYSA-N 0.000 description 1
- AAKSEOXSZOLSTK-UHFFFAOYSA-N 2,2-dimethyl-4-(4-morpholin-4-yl-1,3,5-triazin-2-yl)morpholine Chemical compound CC1(OCCN(C1)C1=NC(=NC=N1)N1CCOCC1)C AAKSEOXSZOLSTK-UHFFFAOYSA-N 0.000 description 1
- BVVMNSNLWMCMOP-UHFFFAOYSA-N 2,2-dimethylmorpholin-4-ium;chloride Chemical compound Cl.CC1(C)CNCCO1 BVVMNSNLWMCMOP-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- DPVIABCMTHHTGB-UHFFFAOYSA-N 2,4,6-trichloropyrimidine Chemical compound ClC1=CC(Cl)=NC(Cl)=N1 DPVIABCMTHHTGB-UHFFFAOYSA-N 0.000 description 1
- LRYSHDDWCVYSPV-UHFFFAOYSA-N 2-(difluoromethyl)-1-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)benzimidazol-4-amine Chemical compound FC(F)C1=NC=2C(N)=CC=CC=2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCOCC1 LRYSHDDWCVYSPV-UHFFFAOYSA-N 0.000 description 1
- FJKFWCUEXVBHJW-UHFFFAOYSA-N 2-(difluoromethyl)-1-[4-(2,6-dimethylmorpholin-4-yl)-6-morpholin-4-ylpyrimidin-2-yl]benzimidazol-4-ol Chemical compound C1C(C)OC(C)CN1C1=CC(N2CCOCC2)=NC(N2C3=CC=CC(O)=C3N=C2C(F)F)=N1 FJKFWCUEXVBHJW-UHFFFAOYSA-N 0.000 description 1
- WURYBQOOPXPQBM-UHFFFAOYSA-N 2-(difluoromethyl)-3-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)benzimidazol-5-ol Chemical compound C12=CC(O)=CC=C2N=C(C(F)F)N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCOCC1 WURYBQOOPXPQBM-UHFFFAOYSA-N 0.000 description 1
- UOCGIKDERISBDO-UHFFFAOYSA-N 2-(difluoromethyl)-4-methoxy-1h-benzimidazole Chemical compound COC1=CC=CC2=C1NC(C(F)F)=N2 UOCGIKDERISBDO-UHFFFAOYSA-N 0.000 description 1
- MXFMPTXDHSDMTI-UHFFFAOYSA-N 2-(trifluoromethyl)-1h-benzimidazole Chemical compound C1=CC=C2NC(C(F)(F)F)=NC2=C1 MXFMPTXDHSDMTI-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 1
- PLYTVAFAKDFFKM-UHFFFAOYSA-N 3,4-dimethylmorpholine Chemical compound CC1COCCN1C PLYTVAFAKDFFKM-UHFFFAOYSA-N 0.000 description 1
- GDSLUYKCPYECNN-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(4-fluorophenyl)methyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC=C(C=C2)F)C=CC=1 GDSLUYKCPYECNN-UHFFFAOYSA-N 0.000 description 1
- ZNVBTSSQJUEQRL-UHFFFAOYSA-N 3-[4-[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]piperazin-1-yl]propan-1-ol Chemical compound C1CN(CCCO)CCN1C1=NC(N2CCOCC2)=NC(N2C3=CC=CC=C3N=C2C(F)F)=N1 ZNVBTSSQJUEQRL-UHFFFAOYSA-N 0.000 description 1
- XJPZKYIHCLDXST-UHFFFAOYSA-N 4,6-dichloropyrimidine Chemical compound ClC1=CC(Cl)=NC=N1 XJPZKYIHCLDXST-UHFFFAOYSA-N 0.000 description 1
- IHNXOSXOGIFEBC-UHFFFAOYSA-N 4-[2-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-morpholin-4-ylpyrimidin-4-yl]-2,2-dimethylmorpholine Chemical compound FC(F)C1=NC=2C(OC)=CC=CC=2N1C(N=1)=NC(N2CCOCC2)=CC=1N1CCOC(C)(C)C1 IHNXOSXOGIFEBC-UHFFFAOYSA-N 0.000 description 1
- BRPZRXMDFJMNNL-UHFFFAOYSA-N 4-[4-[2-(difluoromethyl)-5,6-dimethylbenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]morpholine Chemical compound C1=2C=C(C)C(C)=CC=2N=C(C(F)F)N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCOCC1 BRPZRXMDFJMNNL-UHFFFAOYSA-N 0.000 description 1
- BXNDUOXZCCBUDQ-UHFFFAOYSA-N 4-[4-[2-(difluoromethyl)benzimidazol-1-yl]-1,3,5-triazin-2-yl]morpholine Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC=NC=1N1CCOCC1 BXNDUOXZCCBUDQ-UHFFFAOYSA-N 0.000 description 1
- SVPHVFRPVYPKRQ-UHFFFAOYSA-N 4-[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]piperazine-1-carbaldehyde Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCN(C=O)CC1 SVPHVFRPVYPKRQ-UHFFFAOYSA-N 0.000 description 1
- AJQZNMCGFMDKGJ-UHFFFAOYSA-N 4-[4-chloro-6-[2-(difluoromethyl)benzimidazol-1-yl]-1,3,5-triazin-2-yl]morpholine Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(Cl)=NC=1N1CCOCC1 AJQZNMCGFMDKGJ-UHFFFAOYSA-N 0.000 description 1
- KEINCPBIVGNTSZ-UHFFFAOYSA-N 4-methoxy-1h-benzimidazole Chemical compound COC1=CC=CC2=C1N=CN2 KEINCPBIVGNTSZ-UHFFFAOYSA-N 0.000 description 1
- DUIMWXDLDBNUFD-UHFFFAOYSA-N 4-pyrimidin-2-ylmorpholine Chemical compound C1COCCN1C1=NC=CC=N1 DUIMWXDLDBNUFD-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
- RJNTYCYJINGHMX-TXEJJXNPSA-N C[C@@H]1CN(C[C@@H](O1)C)C2=NC=NC(=C2)N3CCOCC3 Chemical compound C[C@@H]1CN(C[C@@H](O1)C)C2=NC=NC(=C2)N3CCOCC3 RJNTYCYJINGHMX-TXEJJXNPSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091007958 Class I PI3Ks Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241001125840 Coryphaenidae Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 101700012268 Holin Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000907681 Morpho Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 241000609816 Pantholops hodgsonii Species 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 208000000277 Splenic Neoplasms Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- XSHSHCSURLTWSV-UHFFFAOYSA-N [1-[4-[6-amino-4-chloro-2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]pyrrolidin-2-yl]methanol Chemical compound C12=CC(N)=CC(Cl)=C2N=C(C(F)F)N1C(N=1)=NC(N2C(CCC2)CO)=NC=1N1CCOCC1 XSHSHCSURLTWSV-UHFFFAOYSA-N 0.000 description 1
- PPQCLJVVHUMLGF-UHFFFAOYSA-N [4-[2-[2-(difluoromethyl)-4-hydroxybenzimidazol-1-yl]-6-morpholin-4-ylpyrimidin-4-yl]piperazin-1-yl]-(furan-2-yl)methanone Chemical class FC(F)C1=NC=2C(O)=CC=CC=2N1C(N=1)=NC(N2CCOCC2)=CC=1N(CC1)CCN1C(=O)C1=CC=CO1 PPQCLJVVHUMLGF-UHFFFAOYSA-N 0.000 description 1
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- FGDQGIKMWOAFIK-UHFFFAOYSA-N acetonitrile;phosphoric acid Chemical compound CC#N.OP(O)(O)=O FGDQGIKMWOAFIK-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000009390 immune abnormality Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 208000014432 malignant adrenal gland pheochromocytoma Diseases 0.000 description 1
- 208000016848 malignant germ cell tumor Diseases 0.000 description 1
- 201000006782 malignant pheochromocytoma Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000000349 mediastinal cancer Diseases 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 208000018280 neoplasm of mediastinum Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- HVVNJUAVDAZWCB-UHFFFAOYSA-N prolinol Chemical compound OCC1CCCN1 HVVNJUAVDAZWCB-UHFFFAOYSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000010979 ruby Substances 0.000 description 1
- 229910001750 ruby Inorganic materials 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 201000002471 spleen cancer Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Definitions
- Immunosuppressive agent and antitumor agent comprising heterocyclic compound as active ingredient
- the present invention relates to a novel immunosuppressive agent, and more particularly to an immunosuppressive agent containing a heterocyclic compound of a specific structure as an active ingredient.
- the present invention also relates to the novel compound among the above-mentioned heterocyclic compounds, and further to the use of the novel compound as an antitumor agent.
- diseases in which an immunosuppressant is used include rejection of organs and tissues during transplantation, graft host disease at the time of bone marrow transplantation, inflammatory bowel disease such as ulcerative colitis and Crohn's disease, psoriasis, and the like
- Inflammatory or allergic skin diseases such as atopic dermatitis, inflammatory or allergic respiratory diseases such as chronic obstructive pulmonary disease or asthma, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, autoimmune diseases such as Sidaren syndrome And many other autoimmune diseases.
- immunosuppressants such as cyclophosphamide and methotrexate are also used to treat hematologic tumors such as multiple myeloma, malignant lymphoma and leukemia.
- immunosuppressants may be used in combination with antibiotics even in the treatment of diseases characterized by enhanced immune function associated with infection such as sepsis (Non-patent Document 1).
- non-patent Document 1 Non-patent Document 1
- variable cells involved in the disease are immune cells, ie, T cells, B cells, monocytes, macrophages, NK cells, NKT cells, sickle cells, neutrophils, basophils, eosinophils.
- humoral factors released from immune cells that are not limited to mast cells etc. It includes cells such as platelets, vascular endothelial cells, synoviocytes, osteoclasts, osteoblasts, chondrocytes, tracheal epithelial cells, etc. which are enhanced by cell membrane receptors on immune cells.
- the humoral factor is an autoantibody, it also includes cells in which a target antigen is present.
- Non-Patent Document 1 T. Munster et. Al. Clin. Exp. Rheumatol, 17 (Suppl. L8): S29-S36 (1999)
- Patent Document 1 WO 99Z05138 pamphlet
- Patent Document 2 International Publication No. 00Z43385 brochure
- Patent document 3 International publication 02Z088112 pamphlet
- Patent Document 4 International Publication 2004Z037812 Pamphlet
- Patent Document 5 International Publication No. 2005Z095389 Pamphlet
- PI3K phosphatidylinositol 3-kinase
- Non-patent Document 2 phosphatidylinositol 3-kinase
- PI3K is an enzyme that phosphorylates phosphatidylinositol (PI) on the cell membrane and is classified into three subfamilies based on substrate specificity.
- the product of the present invention specifically inhibits class I PI3K.
- Class I PI3K phosphorylates PI, phosphatidylinositol tetraphosphate, phosphatidylinositol 4, 5, and diphosphate, and phosphatidylinositol triphosphate, phosphatidylinositol 3, 4, diphosphate, phosphatidylinositol 3, 4 , 5, to produce triphosphates.
- the generated phosphatidylinositol 3,4,5,3 phosphate acts as an intracellular second messenger.
- Class I PI3Ks are expressed in various cells and play a wide range of functions such as cell proliferation, cell survival, glucose transport, and cytoskeleton regulation. It has been made clear that development and signal transduction of B cells and T cells are impaired in animals knocked out of the PI3K gene. In addition, it is also known that mast cell degranulation and leukocyte migration are also impaired (Non-patent Document 3).
- Hematological malignancies are characterized by the enhancement of spontaneous cell division of immune system cells and suppression of apoptosis. Also in hematological malignancies, phosphatidylinositol 3, 4, 5, 3 phosphate is dephosphorylated PTEN protein Abnormalities in PI3K force scale such as decreased A1 and increased Akt phosphorylation have been reported (Non-patent Document 6). In addition, it has been revealed that inhibition of PI3K suppresses the division of various blood tumor cells and induces apoptosis (for example, Non-patent Document 7).
- Rheumatoid arthritis is a disease characterized by immune abnormalities and hypertrophy of synovial tissue. Hypertrophy of synovial tissue is known to be due to suppression of synovial cell proliferation and apoptosis. Inflammatory synovial tissues of rheumatoid arthritis patients have increased phosphorylation of Akt by PI3K activity (non-patent literature 8), and in in vitro experiments, inhibition of synoviocyte proliferation and apoptosis is PI 3K It has also been clarified that normalization is achieved by inhibiting H. (Non-patent Document 9).
- wartmannin and LY294002 have not been clinically applied because of toxicity.
- Non Patent Literature 2 S. Yaguchi et al, 96th Annual Meeting of the AACR, Anaheim, CA, USA. April 16-20, 2005, # 1691.
- Non-Patent Document 3 R. Wetzker and C. Rommel, Current Pharmaceutical Design, 2004, 10, 1915-1922
- Non-patent document 4 A. C. Donahue and D. A. Fruitan, J Immunol. 2003, 170, 5851-5860
- Non-patent document 5 S. G. Ward et al., Eur J Immunol. 1995, 25, 526-532
- Non-Patent Document 6 P. Workmann, Biochem. Soc. Trans. 2004, 32, 393-396
- Non-patent literature 7 S. Uddin et al., Biochem. Biophys. Res. Commun. 2004320, 932-938
- Non-patent literature 8 H. Zhang et al., Arthritis Rheum 2001, 44, 1555-1567
- Non-patent literature 9 T. Miyashita et al., Biochem Biophys Res Commun 2003, 312, 397-4
- heterocyclic compound of Patent Literatures 1, 2, 3, 4 and 5 include autoimmune diseases, organ transplantation, allergic diseases, blood tumors, sepsis. It is thought that heterocyclic compound of the following general formula (I) is effective as a result of earnestly research, considering that it may be a useful compound also for diseases in which immunosuppressants such as The present invention has been completed by finding certain things.
- X is a nitrogen atom or CH; R and R are both or either a hydrogen atom or a hydroxyl
- R 1 is a hydrogen atom, a ditrifluoromethyl group, an amino group, C 1 -C alkyl Amino group, methyl, hydroxymethyl group; R, R is a hydrogen atom, C-C alkyl group; R is
- -C alkyl group may be substituted), piperidino (1-2 oxygen atoms, hydroxy
- 1,4-diazepano 1-2 oxygen atoms, nitrogen at position 4 is formyl, C-C hydroxyalkyl, C-C
- any one of R 1 and R 2 is a hydroxyl group.
- immunosuppressants wherein the hydroxyl group, R is trifluoromethyl.
- both R and R are hydrogen, and R is trifluoromethyl.
- R is 4-acetylbiperazine.
- An epidemic inhibitor is also provided.
- the target disease is rejection or graft host disease; inflammatory bowel disease such as ulcerative colitis or Crohn's disease; inflammatory disease such as psoriasis or atopic dermatitis! Is an allergic skin disease ; Inflammatory diseases such as obstructive pulmonary disease and asthma are allergic respiratory diseases; rheumatoid arthritis, systemic lupus erythematosus, scleroderma, autoimmune diseases such as Shedalen syndrome; malignant lymphoma, multiple myeloma, chronic leukemia, Acute leukemia, hematologic tumors such as myeloid leukemia; sepsis, fulminant hepatitis, etc.
- any one of R 1 and R 2 is a hydroxyl group.
- PI3K inhibitors are provided.
- R 2 or R is
- a PI3K inhibitor is provided wherein the hydroxyl group, R is trifluoromethyl.
- PI wherein both R and R are hydrogen and R is difluoromethyl A 3K inhibitor is provided. Furthermore, in formula (I), R is 4-acetylbiperazine.
- the target disease is rejection or graft host disease; inflammatory bowel disease such as ulcerative colitis or Crohn's disease; inflammatory disease such as psoriasis or atopic dermatitis! Is an allergic skin disease ; Inflammatory diseases such as obstructive pulmonary disease and asthma are allergic respiratory diseases; rheumatoid arthritis, systemic lupus erythematosus, scleroderma, autoimmune diseases such as Shedalen syndrome; malignant lymphoma, multiple myeloma, chronic leukemia, Acute leukemia, such as hematologic tumors; sepsis, fulminant hepatitis, etc.
- inflammatory bowel disease such as ulcerative colitis or Crohn's disease
- inflammatory disease such as psoriasis or atopic dermatitis! Is an allergic skin disease
- Inflammatory diseases such as obstructive pulmonary disease and asthma are allergic respiratory diseases; rheumatoid arthritis,
- ⁇ is 0 to 2; ⁇ is a nitrogen atom or CH; Y is-(CH 2) n-; n is 1 to 2;
- 1 or 2 or any one of them is a hydrogen atom, a hydroxyl group, a halogen, an amino group, a C—C alkyl
- R is hydrogen atom
- R is a hydrogen atom, a C-C alkyl group; R is a hydrogen atom, a C-C alkyl group, formyl,
- R is a hydrogen atom, a C—C alkyl group
- R is a hydrogen atom, C—C
- the present inventors have also found a new use as an antitumor agent for the novel compound represented by the above formula ( ⁇ ).
- the present invention also relates to an antitumor agent which comprises a compound of formula ( ⁇ ) as an active ingredient.
- Target diseases include, but are not limited to, lung cancer, prostate cancer, breast cancer, colon cancer, gastric cancer, spleen cancer, liver cancer, esophageal cancer, brain cancer, ovarian cancer, uterine cancer, malignant melanoma, kidney cancer, head and neck cancer, skin Cancer, bladder cancer, osteosarcoma, biliary tract cancer, vulvar cancer, testicular cancer, testicular cancer, penile cancer, rectal cancer, mediastinal tumor, urothelial cancer, choriocarcinoma, soft tissue sarcoma, thyroid cancer, parathyroid cancer, pararenal cancer, malignant Pheochromocytoma, germ cell tumor and the like.
- the present invention also relates to the following various embodiments.
- the present invention also relates to the following various embodiments.
- X is a nitrogen atom or CH; R and R are both or either a hydrogen atom or a hydroxyl
- R 1 is a hydrogen atom, a ditrifluoromethyl group, an amino group, C 1 -C alkyl
- R is a hydrogen atom, C-C alkyl group; R is
- -C alkyl group may be substituted), piperidino (1-2 oxygen atoms, hydroxy
- 1,4-diazepano 1-2 oxygen atoms, nitrogen at position 4 is formyl, C-C hydroxyalkyl, C-C
- the invention relates to an immunosuppressive method comprising administering to a mammal an amount.
- one of R 1 and R 2 is a hydroxyl group
- one of R 2 and R is a hydroxyl group, and R is
- any of R and R is hydrogen
- R is diphenyl
- Target diseases include rejection and graft host disease; ulcerative colitis and Crohn's disease Inflammatory bowel diseases such as inflammation; Inflammatory diseases such as psoriasis and atopic dermatitis !, allergic skin diseases such as obstructive pulmonary disease and asthma, allergic respiratory diseases such as obstructive pulmonary disease and asthma; Autoimmune diseases such as lupus erythematosus and scleroderma, Shida- Spotify syndrome; Hematologic tumors such as malignant lymphoma, multiple myeloma, chronic leukemia and acute leukemia; sepsis and fulminant hepatitis.
- n 0 to 2;
- X is a nitrogen atom or CH;
- Y is-(CH2) n-;
- n is 1 to 2;
- 1 or 2 or any one of them is a hydrogen atom, a hydroxyl group, a halogen, an amino group, a C—C alkyl
- R is hydrogen atom
- R is a hydrogen atom, C 1 -C alkyl group; R is a hydrogen atom, C 1 -C alkyl group, formyl,
- Treatment of a tumor comprising administering to the patient a therapeutically effective amount of a heterocyclic compound represented by aromatic carbonyl, benzyl carbonyl, displacement lvamoyl or a pharmaceutically acceptable salt thereof On how to do it.
- a heterocyclic compound represented by aromatic carbonyl, benzyl carbonyl, displacement lvamoyl or a pharmaceutically acceptable salt thereof On how to do it.
- the present invention provides a compound of general formula (II)
- n 0 to 2;
- X is a nitrogen atom or CH;
- Y is-(CH2) n-;
- n is 1 to 2;
- 1 or 2 or any one of them is a hydrogen atom, a hydroxyl group, a halogen, an amino group, a C—C alkyl
- R is hydrogen atom
- R is a hydrogen atom, C 1 -C alkyl group; R is a hydrogen atom, C 1 -C alkyl group, formyl,
- a therapeutically effective amount of a heterocyclic compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier as represented by: aromatic carbonyl, benzyl carbonyl, displacement lvamoyl It relates to an inhibiting composition.
- a composition comprising a therapeutically effective amount of a heterocyclic compound of the general formula (II) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- a pharmaceutical composition more preferably to an antitumor composition.
- the present invention also relates to the following various embodiments.
- the present invention relates to the general formula (I)
- X represents a nitrogen atom or CH; R and R both or either are a hydrogen atom or a hydroxyl Sill, halogen, amino, C-C alkylamino, C-C alkoxy, C-Ca
- R 1 is a hydrogen atom, a ditrifluoromethyl group, an amino group, C 1 -C alkyl
- R is a hydrogen atom, C-C alkyl group; R is
- -C alkyl group may be substituted), piperidino (1-2 oxygen atoms, hydroxy
- 1,4-diazepano 1-2 oxygen atoms, nitrogen at position 4 is formyl, C-C hydroxyalkyl, C-C
- Group power of Rubamo dolphin which is substituted by a selected substituent, which may be substituted with selected substituent (s);), and the therapeutically effective of the heterocyclic compound or pharmaceutically acceptable salt thereof
- a method of PI3K inhibition comprising administering a dose to a mammal.
- one of R 1 and R 2 is a hydroxyl group
- One of 2 is a hydroxyl group
- any of R and R is hydrogen
- R is diphenyl
- Target diseases include rejection and graft host disease; inflammatory bowel diseases such as ulcerative colitis and Crohn's disease; inflammatory diseases such as psoriasis and atopic dermatitis !, allergic skin diseases; Inflammatory diseases such as allergic lung disease and asthma are allergic respiratory diseases; autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, scleroderma and Shidaren syndrome; malignant lymphoma, multiple myeloma, chronic leukemia, acute leukemia Hematological tumors such as sepsis and fulminant hepatitis.
- the present invention provides compounds of general formula (I)
- X is a nitrogen atom or CH; R and R are both or either a hydrogen atom or a hydroxyl
- R 1 is a hydrogen atom, a ditrifluoromethyl group, an amino group, C 1 -C alkyl
- R is a hydrogen atom, C-C alkyl group; R is
- -C alkyl group may be substituted), piperidino (1-2 oxygen atoms, hydroxy
- 1,4-diazepano 1-2 oxygen atoms, nitrogen at position 4 is formyl, C-C hydroxyalkyl, C-C
- a therapeutically effective amount of a heterocyclic compound or a pharmaceutically acceptable compound thereof, wherein PI3K inhibitory composition containing a salt and a pharmaceutically acceptable carrier containing a salt and a pharmaceutically acceptable carrier.
- a composition comprising a therapeutically effective amount of a heterocyclic compound, or a pharmaceutically acceptable salt thereof, represented by the general formula ( ⁇ ), in particular a pharmaceutically acceptable carrier It relates to a pharmaceutical composition, more preferably a PI3K inhibitory composition.
- X is a nitrogen atom or CH; R and R are both or either a hydrogen atom or a hydroxyl
- R 1 is a hydrogen atom, a ditrifluoromethyl group, an amino group, C 1 -C alkyl
- R is a hydrogen atom, C-C alkyl group; R is
- -C alkyl group may be substituted), piperidino (1-2 oxygen atoms, hydroxy
- 1,4-diazepano 1-2 oxygen atoms, nitrogen at position 4 is formyl, C-C hydroxyalkyl, C-C
- one of R 1 and R 2 is a hydroxyl group and
- one of R 2 and R is a hydroxyl group, and R is
- any of R and R is hydrogen
- R is diphenyl
- Target diseases include rejection and graft host disease; ulcerative colitis and Crohn's disease Inflammatory bowel diseases such as inflammation; Inflammatory diseases such as psoriasis and atopic dermatitis !, allergic skin diseases such as obstructive pulmonary disease and asthma, allergic respiratory diseases such as obstructive pulmonary disease and asthma; Autoimmune diseases such as lupus erythematosus and scleroderma, Shida- Spotify syndrome; Hematologic tumors such as malignant lymphoma, multiple myeloma, chronic leukemia and acute leukemia; sepsis and fulminant hepatitis.
- n 0 to 2;
- X is a nitrogen atom or CH;
- Y is-(CH2) n-;
- n is 1 to 2;
- 1 or 2 or any one of them is a hydrogen atom, a hydroxyl group, a halogen, an amino group, a C—C alkyl
- R is hydrogen atom
- R is a hydrogen atom, a C-C alkyl group; R is a hydrogen atom, a C-C alkyl group, formyl,
- X is a nitrogen atom or CH; R and R are both or either a hydrogen atom or a hydroxyl
- R 1 is a hydrogen atom, a ditrifluoromethyl group, an amino group, C 1 -C alkyl
- R is a hydrogen atom, C-C alkyl group; R is
- -C alkyl group may be substituted), piperidino (1-2 oxygen atoms, hydroxy
- 1,4-diazepano 1-2 oxygen atoms, nitrogen at position 4 is formyl, C-C hydroxyalkyl, C-C
- one of R 1 and R 2 is a hydroxyl group
- one of R 2 and R is a hydroxyl group, and R is
- any of R and R is hydrogen
- R is diphenyl
- Target diseases include rejection and graft host disease; ulcerative colitis and Crohn's disease Inflammatory bowel diseases such as inflammation; Inflammatory diseases such as psoriasis and atopic dermatitis !, allergic skin diseases such as obstructive pulmonary disease and asthma, allergic respiratory diseases such as obstructive pulmonary disease and asthma; Autoimmune diseases such as lupus erythematosus and scleroderma, Shida- Spotify syndrome; Hematologic tumors such as malignant lymphoma, multiple myeloma, chronic leukemia and acute leukemia; sepsis and fulminant hepatitis.
- the agent of the present invention is effective in the prophylaxis or treatment of diseases associated with PI3K, such as autoimmune diseases, organ transplantation, allergic or inflammatory diseases, blood tumors, sepsis and the like, and treatment of tumors.
- diseases associated with PI3K such as autoimmune diseases, organ transplantation, allergic or inflammatory diseases, blood tumors, sepsis and the like, and treatment of tumors.
- FIG. 1 shows the effect of test substances on human peripheral blood mononuclear cell CD69 expression and CD40L expression by anti-human CD3 antibody and anti-human CD28 antibody.
- FIG. 2 This is a graph showing the change in rat hindlimb volume after the onset of arthritis by comparing the test substance with the control group.
- FIG. 3 This is a graph showing the change in arthritis score of post-arthritic force comparison between the test substance and the control group.
- FIG. 4 This is a graph showing the test substance and the control group in the human B lymphoma transplantation model.
- the heterocyclic compound used in the present invention has the general formula (I)
- X is a nitrogen atom or CH; R and R are both or either a hydrogen atom or a hydroxyl
- R 1 is a hydrogen atom, a ditrifluoromethyl group, an amino group, C 1 -C alkyl
- R is a hydrogen atom, C-C alkyl group; R is
- -C alkyl group may be substituted), piperidino (1-2 oxygen atoms, hydroxy
- 1,4-diazepano 1-2 oxygen atoms, nitrogen at position 4 is formyl, C-C hydroxyalkyl, C-C
- Group power of Rubamo dolphins which may be substituted by a selected substituent, which may represent;), or a pharmaceutically acceptable salt thereof.
- C-C means, without limitation, a group having 1 to 6 carbon atoms.
- C alkyl is methyl, ethyl, n-propyl, iso-propyl, n-butyl, tert
- linear or branched alkyl groups such as -butyl, n-pentyl, n-hexyl and the like.
- C 1 -C alkoxy methoxy, ethoxy, n-propoxy, isopropoxy, n
- a hydroxy group is attached to any carbon atom of the group defined by the above "C-C alkyl" Means a group that
- heterocyclic compound has an asymmetric carbon atom in the structure
- isomers derived from the asymmetric carbon atom and a mixture (racemate) thereof are present, and all of them are compounds of the present invention. Shall be included.
- the heterocyclic compound used as an active ingredient of the present invention may be in the form of an acid addition salt as a pharmaceutically acceptable salt.
- Suitable acid addition salts include, for example, hydrochlorides, sulfates, hydrobromides, nitrates, phosphates and the like with inorganic acid salts, and acetates, sulfates, propionates, glycolic acids with organic acid salts and the like.
- Salt lactate, pyruvate, malonate, succinate, maleate, fumarate, malate, tartrate, citrate, benzoate, cinnamate, methanesulfonate, benzene Sulfonate, p-toluenesulfonate, salicylate and the like are used.
- the compounds that can be used as the active ingredient of the present invention include, for example, the following heterocyclic compounds: The present invention is not limited thereto.
- the agent of the present invention suppresses the reaction to T cells and B cells by Con A, LPS, 3G gM antibody, anti-CD3 antibody + anti-CD28 antibody as demonstrated in the examples described later. It became clear from the above that it exerts PI3K inhibitory action in immune system cells. That is, the drug of the present invention can be used for the treatment or prevention of immune system diseases based on PI3K hyperfunction.
- immune diseases based on the enhancement of PI3K function include autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus and Shedadaren syndrome; pleurisy, glomerulonephritis, thyroiditis, splenitis, autoimmune diseases such as bone destruction Organ damage caused by tissue rejection, tissue graft rejection, graft host disease at the time of bone marrow transplantation, inflammatory bowel disease such as ulcerative colitis and Crohn's disease, inflammatory inflammation such as psoriasis and dermatitis, Are allergic skin diseases such as chronic obstructive pulmonary disease and asthma, etc.
- autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus and Shedadaren syndrome
- pleurisy glomerulonephritis, thyroiditis, splenitis
- autoimmune diseases such as bone destruction Organ damage caused by tissue rejection, tissue graft rejection, graft
- allergic respiratory diseases are allergic respiratory diseases; allergic conjunctivitis and rhinitis; B lymphoma, T lymphoma, myelocytic leukemia, etc. Originating from cells of immune system Hematological malignancies; Diseases such as sepsis due to infections such as palladium-negative bacteria and coronavirus, severe acute respiratory syndrome, and fulminant hepatitis.
- the agent of the present invention can be applied to mammals such as humans, dogs, cats, rabbits, animals, mice, rats, mice, etc.
- Administration method, dosage form, administration when applied to humans, in particular. explain the amount.
- the drug of the present invention can be administered orally or parenterally, and tablets, coated tablets, powders, granules, capsules, microcapsules, syrups and the like can be used as dosage forms for oral administration.
- tablets, coated tablets, powders, granules, capsules, microcapsules, syrups and the like can be used as dosage forms for oral administration.
- parenteral administration eye drops, inhalants, injections (including lyophilizers for injection which are used at the time of use), suppositories, poultices and the like can be used.
- the preparation of these dosage forms includes pharmaceutically acceptable excipients, binders, lubricants, disintegrants, suspending agents, emulsifiers, preservatives, stabilizers and dispersants such as lactose, sucrose, It is carried out using starch, dextrin, crystalline cellulose, kaolin, calcium carbonate, talc, magnesium stearate, distilled water or saline.
- the dose of the active ingredient varies depending on the patient's symptoms, age, body weight, etc., but for adults weighing 60 kg, the daily dose is 10 to 500 mg. It can be divided into three doses.
- the force that differs according to the patient's condition is different as a daily dose for adults 1 to 3: L00 ⁇ g 2-3 It can be administered in divided doses.
- heterocyclic ring compounds of the general formula (I), prepared using the methods of the examples of the patent documents 3, 4 and 5, are shown here.
- Patent Documents 1 to 3 were synthesized with reference.
- 6-chloro-2- (2-difluoromethylbenzimidazole-1-yl) -4-morpholino-1,3,5-triazine (3.66 g, 10 mmol), 1-acetylbiperazine ( A mixture of 1.40 g, 1 l mmol), potassium carbonate (1.38 g, 10 mmol), DMF (30 ml) was stirred at room temperature for 16 hours. The reaction solution was poured into water and extracted with dichloromethane.
- the extract is dried over anhydrous sodium sulfate and concentrated under reduced pressure, and the residue is purified through a silica gel column to obtain the target substance 4- (4-acetylbiperazine-l-yl) -2- (2-) Difluoromethylbenzimidazole-1-yl) -6-morpholino-1,3,5 triazine (354 mg, 7.7 mmol) was obtained as colorless crystals in a yield of 77%.
- test methods for confirming the pharmacological effects and toxicity of the heterocyclic compound represented by the general formula (I) and the results thereof are shown below.
- the compound number of the test substance corresponds to the compound number assigned to the above-mentioned heterocyclic compound name.
- C57BL / 6N female mice (8-week-old, purchased from Nihon Chisyu 's Reva company) force prepared spleen cells in RPMI 1640 medium (10% fetal bovine serum, 10 mM HEPES, 1 mM pyruvate, 4. The cells were suspended in 5 g / L glucose, 100 units Z mL penicillin, 0.1 mg / mL streptomycin (2 ⁇ 10 6 cells Z mL), and seeded in 96-well plates at a volume of 0.225 mL per well.
- Concanaparin A Con A, 3 ⁇ g / mL
- Lipopolysaccharide LPS, lOO / z gZmL
- anti-mouse IgM antibody 100 ⁇ g ZmL
- the cells were cultured for 3 days under the conditions of 5% carbon dioxide and a temperature of 37 ° C.
- the fluorescence intensity of 590 nm at an excitation wavelength of 530 nm was changed to Cytoflour 4000 ( Measurement was performed using Applied Systems Co., Ltd.).
- Table 1 it was found that the s-triazine analog suppresses the proliferation of mouse spleen cells by Con A, LPS, or anti-IgM antibody.
- Human peripheral blood mononuclear cell proliferation inhibition test 4 mL of blood collected from healthy subjects was placed on 3 mL of monopoly separation solution, centrifuged, and then the mononuclear cells (PBMC) fraction was collected.
- the PBMCs were washed with physiological saline and then suspended in RPMI 1640 medium (containing 10% fetal bovine serum, 10 mM HEPES, 1 mM pyruvate, 4.5 g / L glucose) (1 ⁇ 10 5 cells Z mL).
- anti-CD28 antibody (1 ⁇ g ZmL) was added to the suspension, and then seeded on an anti-human CD3 T cell activation plate (BD Biosciences) at a volume of 0.135 mL per well.
- test substance diluted stepwise was added to each well and cultured under the conditions of carbon dioxide 5% and temperature 37 ° C.
- 50 ⁇ l of Alamar Blue solution was added per 1 well, and after culturing for 1 day, the fluorescence intensity of 590 nm at an excitation wavelength of 530 nm was measured using Cytoflour 4000 (manufactured by Applied Biosystems).
- Cytoflour 4000 manufactured by Applied Biosystems
- Human peripheral blood mononuclear cell activation inhibition test According to the method of Test Example 2, PBMC are separated from human peripheral blood and suspended in RPMI 1640 medium (containing 10% fetal bovine serum, 10 mM HEPES, 1 mM pyruvate, 4.5 g / L glucose) (2 ⁇ 10 6). Cells / mL) were seeded on a 96-well plate at a volume of 0.225 mL per well. The test substance was added to each well, and then anti-CD3 antibody (2 / z gZmL) anti-CD28 antibody (1 g ZmL) was added.
- RPMI 1640 medium containing 10% fetal bovine serum, 10 mM HEPES, 1 mM pyruvate, 4.5 g / L glucose
- Adjuvant arthritis was induced by intradermal administration of Mycobacterium butyricum suspended in Freund's incomplete adjuvant on the ridges of Lewis male rats (7-week-old, purchased from Japan Chisya 's Reva company). Then, an adjuvant arthritis was induced and a test substance suspended in 0.5% hydroxypropyl cellulose (HPC) on day 10 was orally administered daily.
- HPC hydroxypropyl cellulose
- the post-arthritic force was also measured for the rat hindlimb volume using a footpad edema volumetric measurement apparatus (TK105, manufactured by Physioc).
- TK105 footpad edema volumetric measurement apparatus
- Ushib type collagen suspended in complete adjuvant of Freund's complete adjuvant in the ridges of DBA1 male mice (7 weeks old, purchased from Nihon Chirushu's Riba) is experiment 1 and 21 days Intradermal administration. Then, on the 28th day when 50% mice developed arthritis, the test substance suspended in 0.5% hydroxypropyl cellulose (HPC) was also orally administered on a daily basis. The drug effect was evaluated by scoring arthritis. That is, 1 limb, no symptoms: 0, 1 joint redness and swelling: 1 and 2 or more redness and swelling: 2 whole limb swelling and swelling: 3 and maximum redness of whole leg , Swelling: As 4, the degree of arthritis was evaluated.
- HPC hydroxypropyl cellulose
- Synovial cells HIG- 82 (4 X 10 4 cells Z mL) suspended in HAM medium (containing 10% fetal bovine serum, 25 mM HEPES, and 0.1 mg Z mL kanamycin) were added to 0. Sowed at a volume of Then, 15 liters of the test substance diluted stepwise was added to each well and cultured under the conditions of 5% carbon dioxide and 37 ° C. Next, on the day of seeding and on the third day of culture, 50 ⁇ l per well of Alama Blue solution was added, and after culturing for 1 day, the fluorescence intensity of 590 nm at an excitation wavelength of 530 nm ) was used. As shown in Table 3, it was found that the s-triazine analogues inhibited Japanese synovial cell division.
- C57BL / 6N female mice (8 to 10 weeks old, purchased from Nippon Chirus' Riba One) as Stimulator cells, Spleen cells for which the force was also prepared, and BALB / c female mice (8 to 10 weeks) as Responder cells
- the peripheral lymph node mononuclear cells whose age and power (purchased from Nihon Chirusha 'Riba 1 company) were also prepared were used.
- Each cell was suspended in RPMI 1640 medium (10% fetal bovine serum, 100 units / mL penicillin, 0.1 mg mg ZmL streptomycin) (2 X 10 6 cells / mL) o and treated with mitomycin C (50 mg Z mL, 30 Min) was added to the responder cell (50 L) to the responder celKlOO / z L).
- mitomycin C 50 mg Z mL, 30 Min
- cell proliferation was examined with the BrdU cell proliferation kit (Lelibiochem). As a result, as shown in Table 4, it was found that the s-triazine analog suppresses the mixed lymphocyte reaction.
- Daudi cells (5 ⁇ 10 5 cells / mL) suspended in RPMI 1640 medium (containing 10% fetal bovine serum, 10 mM HEPES, ImM pyruvate, 4.5 g / L glucose, 100 units ZmL penicillin, 0.1 mg / mL streptomycin), Jurkat cells (5 ⁇ 10 5 cells / mL), THP-1 cells (5 ⁇ 10 5 cellsZmL), U937 cells (5 ⁇ 10 5 cells / mL), HL60 cells (5 ⁇ 10 5 cells ZmL), 96 wells Plates were seeded at a volume of 0.135 mL per well.
- Daudi cells (1 ⁇ 10 7 cells) cultured in RPMI 1640 medium (containing 10% fetal bovine serum, 10 mM HEPES, ImM pyruvate, 4.5 g / L glucose, 100 units / mL penicillin, 0.1 mg / mL streptomycin) It was transplanted to the chest of 8-week-old NODZSCID mice. The tumor grew to a volume of about 800 mm 3 and the force on day 20 after transplantation was compound 8 (40 Omg Z kg) was administered orally. As a result, Compound 8 suppressed the increase in tumor volume in the model, as shown in FIG.
- mice Male BALBZc male mice (7 weeks old, purchased from Nippon Chirushi's Riba 1) were used for the experiment. After orally administering the test substance suspended in 5% HPC, Galactosamine (800 mg Z kg) and LPS d 10 / z g Z kg) were intraperitoneally administered. Then, the survival rate at 72 hours after administration was determined. As a result, as shown in Table 6, the test compound improved the lethal action of Galactosamine and LPS.
- s-triazine analogues are more safe in addition to in vivo studies such as rat adjuvant arthritis test, mouse collagen arthritis test, human B lymphoma transplantation model, fulminant hepatitis test, single oral dose toxicity test, etc. It turned out to be a high compound.
- the agent of the present invention suppresses the reaction to T cells and B cells by Con A, LPS, anti-IgM antibody, anti-CD3 antibody + anti-CD28 antibody, it can be used in immune system cells! It has become clear that it exerts a PI3K inhibitory effect. That is, the drug of the present invention can be used for the treatment or prevention of immune system diseases based on the enhancement of PI3K function.
- immune diseases based on PI3K hyperactivity include autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and Shiedaren syndrome; pleurisy, glomerulonephritis, thyroiditis, splenitis, and organs associated with autoimmune diseases such as bone destruction.
- tissue transplantation disorders of tissue transplantation; graft host disease at bone marrow transplantation; inflammatory bowel disease such as ulcerative colitis and Crohn's disease; inflammatory or allergic skin disease such as psoriasis or atopic dermatitis ; Chronic obstructive pulmonary disease and inflammatory diseases such as asthma !, allergic respiratory diseases, allergic conjunctivitis and rhinitis; B lymphoma, T lymphoma, myeloid leukemia, etc. Gram-negative bacteria and infections such as coronavirus, sepsis, severe acute respiratory syndrome, and diseases such as fulminant hepatitis.
- Pharmacokinetic tests were conducted using 6-week-old BDF1 male mice.
- the test compound is dissolved in dichloromethane together with 2.5 times the drug weight in amount of hydroxypropylcellulose (low molecular weight) [HPC (L)] and then dried under reduced pressure to give a drug concentration of 20 mg / mL in distilled water. It was suspended.
- the test compound was orally administered at a dose of 200 mg / kg to mice fasted for 16 hours. One hour after administration, blood was collected from the orbits of two mice each to obtain serum.
- Test MCF-7 human breast cancer cells passaged in MEM medium (containing 10% fetal calf serum, 25 mM HEPES and O. lmg / ml kanamycin) under the conditions of 5% carbon dioxide at 37 ° C.
- MEM medium (10% fetal calf serum, 25 mM HEPES, supplemented with O. lmg / ml kanamycin) was added to 4 x 10 4 per 1 m. Cell suspensions were adjusted.
- RPM 11640 medium was diluted with (10% fetal bovine serum, 25 mM HEPES, including O. lmg / ml kanamycin), 2.0 the concentration X 10- 9 ⁇ 2.0 X 10- 4 Adjusted to M.
- 0.1 ml of cell suspension is placed in a 96-well plate and cultured for 24 hours to attach the cells to the microwell plate, then 0.1 ml of the test compound is added, carbon dioxide 5%, temperature 37 ° The cells were cultured in C for 72 hours.
- PC-3 prostate cancer cells 10% fetal calf serum, 2 ⁇ 10 4 single cell suspensions in F12K medium
- A549 lung cancer cells DMEM medium with 10% fetal calf serum, 1.5 x 10 4 single cell suspensions
- WiDr colon cancer cells 10% fetal calf serum, 3 x 10 4 single cell suspensions in MEM medium
- B16F10 melanoma cells 10% fetal bovine serum, 1 x 10 4 single cell suspension in RPMI 1640 medium
- the agent of the present invention can be used for the prophylaxis or treatment of immune system diseases associated with PI3K, such as autoimmune diseases, organ transplantation, allergic or inflammatory diseases, blood tumors, sepsis and the like. It can also be used to treat solid tumors. Furthermore, it can be used as a PI3K inhibitor in the treatment of various diseases.
- immune system diseases associated with PI3K such as autoimmune diseases, organ transplantation, allergic or inflammatory diseases, blood tumors, sepsis and the like. It can also be used to treat solid tumors. Furthermore, it can be used as a PI3K inhibitor in the treatment of various diseases.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020077023354A KR101296884B1 (ko) | 2005-03-11 | 2006-03-13 | 활성 성분으로서 헤테로시클릭 화합물을 포함하는 면역억제제 및 항암제 |
AU2006221285A AU2006221285B2 (en) | 2005-03-11 | 2006-03-13 | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient |
PL06729002T PL1864665T3 (pl) | 2005-03-11 | 2006-03-13 | Środek immunosupresyjny obejmujący związek heterocykliczny jako składnik aktywny |
JP2007507227A JP5089377B2 (ja) | 2005-03-11 | 2006-03-13 | 複素環式化合物を有効成分とする免疫抑制剤及び抗腫瘍剤 |
DK06729002.3T DK1864665T3 (da) | 2005-03-11 | 2006-03-13 | Immunsuppressivt middel indeholdende en heterocyklisk forbindelse som aktiv bestanddel |
CN2006800078885A CN101137382B (zh) | 2005-03-11 | 2006-03-13 | 含有杂环化合物作为活性成分的免疫抑制剂和抗肿瘤剂 |
CA2599879A CA2599879C (en) | 2005-03-11 | 2006-03-13 | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient |
BRPI0608291-2A BRPI0608291A2 (pt) | 2005-03-11 | 2006-03-13 | agente imunossupressor e agente antitumoral que compreendem composto heterocìclico como ingrediente ativo |
ES06729002T ES2395196T3 (es) | 2005-03-11 | 2006-03-13 | Agente inmunosupresor que comprende un compuesto heterocíclico como ingrediente activo |
EP06729002A EP1864665B1 (en) | 2005-03-11 | 2006-03-13 | Immunosuppressive agent comprising a heterocyclic compound as active ingredient |
SI200631382T SI1864665T1 (sl) | 2005-03-11 | 2006-03-13 | Imunosupresivno sredstvo, ki obsega heterociklično spojino kot učinkovino |
US11/847,593 US7750001B2 (en) | 2005-03-11 | 2007-08-30 | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient |
HK08109143.9A HK1118016A1 (en) | 2005-03-11 | 2008-08-18 | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient |
US12/785,683 US8338414B2 (en) | 2005-03-11 | 2010-05-24 | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-069255 | 2005-03-11 | ||
JP2005069255 | 2005-03-11 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/847,593 Continuation US7750001B2 (en) | 2005-03-11 | 2007-08-30 | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006095906A1 true WO2006095906A1 (ja) | 2006-09-14 |
Family
ID=36953490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/304937 WO2006095906A1 (ja) | 2005-03-11 | 2006-03-13 | 複素環式化合物を有効成分とする免疫抑制剤及び抗腫瘍剤 |
Country Status (18)
Country | Link |
---|---|
US (2) | US7750001B2 (ja) |
EP (1) | EP1864665B1 (ja) |
JP (1) | JP5089377B2 (ja) |
KR (1) | KR101296884B1 (ja) |
CN (1) | CN101137382B (ja) |
AU (1) | AU2006221285B2 (ja) |
BR (1) | BRPI0608291A2 (ja) |
CA (1) | CA2599879C (ja) |
CY (1) | CY1112886T1 (ja) |
DK (1) | DK1864665T3 (ja) |
ES (1) | ES2395196T3 (ja) |
HK (1) | HK1118016A1 (ja) |
PL (1) | PL1864665T3 (ja) |
PT (1) | PT1864665E (ja) |
RU (1) | RU2443441C2 (ja) |
SI (1) | SI1864665T1 (ja) |
TW (1) | TWI381841B (ja) |
WO (1) | WO2006095906A1 (ja) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007128672A1 (en) * | 2006-05-03 | 2007-11-15 | Ciba Holding Inc. | Substituted hexahydro-1,4-diazepin-5-ones and compositions stabilized therewith |
WO2008032028A1 (en) * | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 2 -benzimidazolyl- 6 -morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
WO2008032072A1 (en) * | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
WO2008032064A1 (en) * | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | Pyrimidine derivatives |
WO2008032060A1 (en) * | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders |
WO2009066775A1 (ja) | 2007-11-22 | 2009-05-28 | Zenyaku Kogyo Kabushikikaisha | 複素環式化合物の非晶質体、それを含む固体分散体、薬剤、およびその製造法 |
WO2010092962A1 (ja) * | 2009-02-12 | 2010-08-19 | アステラス製薬株式会社 | へテロ環誘導体 |
WO2010110685A2 (en) | 2009-03-27 | 2010-09-30 | Pathway Therapeutics Limited | Pyrimddinyl and 1,3,5-triazinyl benzimtoazole sulfonamides and their use in cancer therapy |
WO2010110686A1 (en) | 2009-03-27 | 2010-09-30 | Pathway Therapeutics Limited | Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy |
WO2011135520A1 (en) | 2010-04-30 | 2011-11-03 | University Of Basel | Piperazinotriazines as pi3k inhibitors for use in the treatment antiproliferative disorders |
WO2012020762A1 (ja) * | 2010-08-10 | 2012-02-16 | アステラス製薬株式会社 | へテロ環化合物 |
JP2012508223A (ja) * | 2008-11-10 | 2012-04-05 | ユニバーシティ オブ バーゼル | トリアジン、ピリミジン、及びピリジン類似体、並びに、治療薬及び診断プローブとしてのそれらの使用 |
US8362241B2 (en) | 2009-04-28 | 2013-01-29 | Amgen Inc. | Inhibitors of PI3 kinase and/or mTOR |
US8486939B2 (en) | 2009-07-07 | 2013-07-16 | Pathway Therapeutics Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
US9056852B2 (en) | 2011-03-28 | 2015-06-16 | Mei Pharma, Inc. | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
JP2017535562A (ja) * | 2014-11-20 | 2017-11-30 | カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ | 抗がん剤としての新規な1,3,5−トリアジン系pi3k阻害剤及びその製造方法 |
WO2018131659A1 (ja) * | 2017-01-11 | 2018-07-19 | 国立研究開発法人国立がん研究センター | 免疫療法剤 |
US10214519B2 (en) | 2016-09-23 | 2019-02-26 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
US10227350B2 (en) | 2016-09-23 | 2019-03-12 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
US10479770B2 (en) | 2016-09-23 | 2019-11-19 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
US10640516B2 (en) | 2014-11-11 | 2020-05-05 | Piqur Therapeutics Ag | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines |
US11304953B2 (en) | 2017-05-23 | 2022-04-19 | Mei Pharma, Inc. | Combination therapy |
US11351176B2 (en) | 2017-08-14 | 2022-06-07 | Mei Pharma, Inc. | Combination therapy |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009120094A2 (en) * | 2008-03-27 | 2009-10-01 | Auckland Uniservices Limited | Substituted pyrimidines and triazines and their use in cancer therapy |
CN102429911A (zh) * | 2011-12-08 | 2012-05-02 | 天津医科大学 | Zstk474在制备治疗自身免性疾病药物方面的应用 |
RU2509770C2 (ru) * | 2012-06-22 | 2014-03-20 | Общество с ограниченной ответственностью "Молекулярные Технологии" | Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных |
WO2015047124A1 (ru) * | 2013-09-26 | 2015-04-02 | Общество с ограниченной ответственностью "Молекулярные Технологии" | Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных |
CN105130960B (zh) * | 2015-07-31 | 2018-07-06 | 沈阳药科大学 | 1,3,5-三嗪类衍生物及其应用 |
RU2637643C1 (ru) * | 2016-09-05 | 2017-12-05 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" (НИИФКИ) | Иммунодепрессант |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1020462A1 (en) * | 1997-07-24 | 2000-07-19 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compounds and antitumor agent containing the same as active ingredient |
WO2000043385A1 (fr) * | 1999-01-25 | 2000-07-27 | Zenyaku Kogyo Kabushiki Kaisha | Composes heterocycliques et agents antitumoraux les comprenant en tant que principe actif |
WO2001091699A2 (en) * | 2000-05-30 | 2001-12-06 | Advanced Research & Technology Institute | Compositions and methods for identifying agents which modulate pten function and pi-3 kinase pathways |
EP1389617A1 (en) * | 2001-04-27 | 2004-02-18 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as active ingredient |
WO2004037812A1 (ja) * | 2002-10-25 | 2004-05-06 | Zenyaku Kogyo Kabushiki Kaisha | 複素環式化合物及びそれを有効成分とする抗腫瘍剤 |
WO2005095389A1 (ja) * | 2004-03-31 | 2005-10-13 | Zenyaku Kogyo Kabushiki Kaisha | 複素環式化合物及びそれを有効成分とする抗悪性腫瘍剤 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2004A (en) * | 1841-03-12 | Improvement in the manner of constructing and propelling steam-vessels | ||
CA1338012C (en) * | 1987-04-27 | 1996-01-30 | John Michael Mccall | Pharmaceutically active amines |
EP0629622B1 (en) | 1992-02-28 | 1998-11-11 | Zenyaku Kogyo Kabushikikaisha | S-triazine derivative and remedy for estrogen-dependent diseases containing the same as active ingredient |
IL110296A (en) * | 1993-07-16 | 1999-12-31 | Smithkline Beecham Corp | Imidazole compounds process for their preparation and pharmaceutical compositions containing them |
DK0640599T3 (da) * | 1993-08-26 | 1998-09-28 | Ono Pharmaceutical Co | 4-Aminopyrimidin-derivater |
US5656643A (en) | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
TW312694B (ja) | 1994-09-26 | 1997-08-11 | Daiichi Seiyaku Co | |
JPH0948776A (ja) | 1994-09-26 | 1997-02-18 | Dai Ichi Seiyaku Co Ltd | ピリミジニルピラゾール誘導体 |
AU2002230098B2 (en) | 2001-01-30 | 2007-06-14 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compounds and cognitive enhancers comprising the same as effective components |
AU2003272972A1 (en) | 2002-10-11 | 2004-05-04 | Kowa Co., Ltd. | Method of treatment for cancer |
EP1569653A1 (en) * | 2002-12-06 | 2005-09-07 | Warner-Lambert Company LLC | Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k |
US20070244110A1 (en) | 2006-04-14 | 2007-10-18 | Zenyaku Kogyo Kabushiki Kaisha | Treatment of prostate cancer, melanoma or hepatic cancer |
-
2006
- 2006-03-13 JP JP2007507227A patent/JP5089377B2/ja active Active
- 2006-03-13 WO PCT/JP2006/304937 patent/WO2006095906A1/ja active Application Filing
- 2006-03-13 AU AU2006221285A patent/AU2006221285B2/en not_active Ceased
- 2006-03-13 RU RU2007137651/04A patent/RU2443441C2/ru not_active IP Right Cessation
- 2006-03-13 KR KR1020077023354A patent/KR101296884B1/ko not_active IP Right Cessation
- 2006-03-13 PL PL06729002T patent/PL1864665T3/pl unknown
- 2006-03-13 BR BRPI0608291-2A patent/BRPI0608291A2/pt not_active IP Right Cessation
- 2006-03-13 CA CA2599879A patent/CA2599879C/en not_active Expired - Fee Related
- 2006-03-13 EP EP06729002A patent/EP1864665B1/en not_active Not-in-force
- 2006-03-13 SI SI200631382T patent/SI1864665T1/sl unknown
- 2006-03-13 CN CN2006800078885A patent/CN101137382B/zh not_active Expired - Fee Related
- 2006-03-13 PT PT06729002T patent/PT1864665E/pt unknown
- 2006-03-13 ES ES06729002T patent/ES2395196T3/es active Active
- 2006-03-13 DK DK06729002.3T patent/DK1864665T3/da active
- 2006-03-13 TW TW095108509A patent/TWI381841B/zh not_active IP Right Cessation
-
2007
- 2007-08-30 US US11/847,593 patent/US7750001B2/en not_active Expired - Fee Related
-
2008
- 2008-08-18 HK HK08109143.9A patent/HK1118016A1/xx not_active IP Right Cessation
-
2010
- 2010-05-24 US US12/785,683 patent/US8338414B2/en active Active
-
2012
- 2012-06-27 CY CY20121100567T patent/CY1112886T1/el unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1020462A1 (en) * | 1997-07-24 | 2000-07-19 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compounds and antitumor agent containing the same as active ingredient |
WO2000043385A1 (fr) * | 1999-01-25 | 2000-07-27 | Zenyaku Kogyo Kabushiki Kaisha | Composes heterocycliques et agents antitumoraux les comprenant en tant que principe actif |
WO2001091699A2 (en) * | 2000-05-30 | 2001-12-06 | Advanced Research & Technology Institute | Compositions and methods for identifying agents which modulate pten function and pi-3 kinase pathways |
EP1389617A1 (en) * | 2001-04-27 | 2004-02-18 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as active ingredient |
WO2004037812A1 (ja) * | 2002-10-25 | 2004-05-06 | Zenyaku Kogyo Kabushiki Kaisha | 複素環式化合物及びそれを有効成分とする抗腫瘍剤 |
WO2005095389A1 (ja) * | 2004-03-31 | 2005-10-13 | Zenyaku Kogyo Kabushiki Kaisha | 複素環式化合物及びそれを有効成分とする抗悪性腫瘍剤 |
Non-Patent Citations (9)
Title |
---|
A. C. DONAHUE; D. A. FRUMAN, J. IMMUNOL., vol. 170, 2003, pages 5851 - 5860 |
H. ZHANG ET AL., ARTHRITIS RHEUM, vol. 44, 2001, pages 1555 - 1567 |
HUANG S. ET AL.: "Rapamycins: mechanism of action and cellular resistance", CANCER BIOL. THER., vol. 2, no. 3, 2003, pages 222 - 232, XP003000061 * |
P. WORKMANN, BIOCHEM. SOC. TRANS., vol. 32, 2004, pages 393 - 396 |
R. WETZKER; C. ROMMEL, CURRENT PHARMACEUTICAL DESIGN, vol. 10, 2004, pages 1915 - 1922 |
S. G. WARD ET AL., EUR J IMMUNOL., vol. 25, 1995, pages 526 - 532 |
S. UDDIN ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 320, 2004, pages 932 - 938 |
S. YAGUCHI ET AL., 96TH ANNUAL MEETING OF THE AACR, 16 April 2005 (2005-04-16), pages 1691 |
T. MIYASHITA ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 312, 2003, pages 397 - 404 |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007128672A1 (en) * | 2006-05-03 | 2007-11-15 | Ciba Holding Inc. | Substituted hexahydro-1,4-diazepin-5-ones and compositions stabilized therewith |
WO2008032028A1 (en) * | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 2 -benzimidazolyl- 6 -morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
WO2008032072A1 (en) * | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
WO2008032064A1 (en) * | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | Pyrimidine derivatives |
WO2008032060A1 (en) * | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders |
KR101576695B1 (ko) * | 2007-11-22 | 2015-12-10 | 젠야쿠코교가부시키가이샤 | 복소환식 화합물의 비정질체, 이를 포함하는 고체 분산체, 약제 및 그 제조법 |
TWI482768B (zh) * | 2007-11-22 | 2015-05-01 | Zenyaku Kogyo Kk | 雜環化合物之非晶質體、含有其之固體分散體、藥劑及其製法 |
AU2008327095B2 (en) * | 2007-11-22 | 2013-07-25 | Ohara Pharmaceutical Co., Ltd. | Amorphous form of heterocyclic compound, solid dispersion and medicinal preparation each comprising the same, and process for production of the same |
WO2009066775A1 (ja) | 2007-11-22 | 2009-05-28 | Zenyaku Kogyo Kabushikikaisha | 複素環式化合物の非晶質体、それを含む固体分散体、薬剤、およびその製造法 |
JPWO2009066775A1 (ja) * | 2007-11-22 | 2011-04-07 | 全薬工業株式会社 | 複素環式化合物の非晶質体、それを含む固体分散体、薬剤、およびその製造法 |
JP5479912B2 (ja) * | 2007-11-22 | 2014-04-23 | 全薬工業株式会社 | 複素環式化合物の非晶質体、それを含む固体分散体、薬剤、およびその製造法 |
EP2409975A1 (en) | 2007-11-22 | 2012-01-25 | Zenyaku Kogyo Kabushikikaisha | Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same |
US8227463B2 (en) | 2007-11-22 | 2012-07-24 | Zenyaku Kogyo Kabushiki Kaisha | Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same |
JP2012508223A (ja) * | 2008-11-10 | 2012-04-05 | ユニバーシティ オブ バーゼル | トリアジン、ピリミジン、及びピリジン類似体、並びに、治療薬及び診断プローブとしてのそれらの使用 |
WO2010092962A1 (ja) * | 2009-02-12 | 2010-08-19 | アステラス製薬株式会社 | へテロ環誘導体 |
US9108980B2 (en) | 2009-03-27 | 2015-08-18 | Vetdc, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
US8461158B2 (en) | 2009-03-27 | 2013-06-11 | Pathway Therapeutics Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
US8772287B2 (en) | 2009-03-27 | 2014-07-08 | Vetdc, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
WO2010110686A1 (en) | 2009-03-27 | 2010-09-30 | Pathway Therapeutics Limited | Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy |
WO2010110685A2 (en) | 2009-03-27 | 2010-09-30 | Pathway Therapeutics Limited | Pyrimddinyl and 1,3,5-triazinyl benzimtoazole sulfonamides and their use in cancer therapy |
US8772480B2 (en) | 2009-04-28 | 2014-07-08 | Amgen Inc. | Inhibitors of PI3 kinase and/or mTOR |
US8362241B2 (en) | 2009-04-28 | 2013-01-29 | Amgen Inc. | Inhibitors of PI3 kinase and/or mTOR |
US8486939B2 (en) | 2009-07-07 | 2013-07-16 | Pathway Therapeutics Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
JP2013525419A (ja) * | 2010-04-30 | 2013-06-20 | ユニバーシティ・オブ・バーゼル | 抗増殖性障害の処置における使用のためのpi3k阻害剤としてのピペラジノトリアジン |
WO2011135520A1 (en) | 2010-04-30 | 2011-11-03 | University Of Basel | Piperazinotriazines as pi3k inhibitors for use in the treatment antiproliferative disorders |
KR101759762B1 (ko) | 2010-08-10 | 2017-07-19 | 아스텔라스세이야쿠 가부시키가이샤 | 헤테로환 화합물 |
US8912180B2 (en) | 2010-08-10 | 2014-12-16 | Astellas Pharma Inc. | Heterocyclic compound |
JPWO2012020762A1 (ja) * | 2010-08-10 | 2013-10-28 | アステラス製薬株式会社 | へテロ環化合物 |
WO2012020762A1 (ja) * | 2010-08-10 | 2012-02-16 | アステラス製薬株式会社 | へテロ環化合物 |
JP5765342B2 (ja) * | 2010-08-10 | 2015-08-19 | アステラス製薬株式会社 | へテロ環化合物 |
EA023931B1 (ru) * | 2010-08-10 | 2016-07-29 | Астеллас Фарма Инк. | Гетероциклическое соединение |
US9056852B2 (en) | 2011-03-28 | 2015-06-16 | Mei Pharma, Inc. | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
US11400097B2 (en) | 2011-03-28 | 2022-08-02 | Mei Pharma, Inc. | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
US10064868B2 (en) | 2011-03-28 | 2018-09-04 | Mei Pharma, Inc. | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
US10335415B2 (en) | 2011-03-28 | 2019-07-02 | Mei Pharma, Inc. | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
US12059422B2 (en) | 2011-03-28 | 2024-08-13 | Mei Pharma, Inc. | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
US10603324B2 (en) | 2011-03-28 | 2020-03-31 | Mei Pharma, Inc. | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
US10640516B2 (en) | 2014-11-11 | 2020-05-05 | Piqur Therapeutics Ag | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines |
US11186591B2 (en) | 2014-11-11 | 2021-11-30 | Universität Basel | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines |
JP2017535562A (ja) * | 2014-11-20 | 2017-11-30 | カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ | 抗がん剤としての新規な1,3,5−トリアジン系pi3k阻害剤及びその製造方法 |
US10214519B2 (en) | 2016-09-23 | 2019-02-26 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
US10227350B2 (en) | 2016-09-23 | 2019-03-12 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
US10479770B2 (en) | 2016-09-23 | 2019-11-19 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
WO2018131659A1 (ja) * | 2017-01-11 | 2018-07-19 | 国立研究開発法人国立がん研究センター | 免疫療法剤 |
JPWO2018131659A1 (ja) * | 2017-01-11 | 2019-12-12 | 国立研究開発法人国立がん研究センター | 免疫療法剤 |
US11304953B2 (en) | 2017-05-23 | 2022-04-19 | Mei Pharma, Inc. | Combination therapy |
US11351176B2 (en) | 2017-08-14 | 2022-06-07 | Mei Pharma, Inc. | Combination therapy |
Also Published As
Publication number | Publication date |
---|---|
TW200642689A (en) | 2006-12-16 |
RU2007137651A (ru) | 2009-04-20 |
US7750001B2 (en) | 2010-07-06 |
EP1864665B1 (en) | 2012-05-16 |
PT1864665E (pt) | 2012-06-27 |
AU2006221285A1 (en) | 2006-09-14 |
BRPI0608291A2 (pt) | 2009-12-22 |
AU2006221285B2 (en) | 2011-03-31 |
US20080113987A1 (en) | 2008-05-15 |
EP1864665A1 (en) | 2007-12-12 |
CY1112886T1 (el) | 2016-04-13 |
JP5089377B2 (ja) | 2012-12-05 |
KR101296884B1 (ko) | 2013-08-14 |
CA2599879C (en) | 2013-07-02 |
CN101137382B (zh) | 2012-11-21 |
US20100267700A1 (en) | 2010-10-21 |
TWI381841B (zh) | 2013-01-11 |
PL1864665T3 (pl) | 2012-10-31 |
CA2599879A1 (en) | 2006-09-14 |
JPWO2006095906A1 (ja) | 2008-08-21 |
KR20070113285A (ko) | 2007-11-28 |
DK1864665T3 (da) | 2012-07-23 |
HK1118016A1 (en) | 2009-01-30 |
SI1864665T1 (sl) | 2012-09-28 |
EP1864665A4 (en) | 2008-06-11 |
RU2443441C2 (ru) | 2012-02-27 |
CN101137382A (zh) | 2008-03-05 |
ES2395196T3 (es) | 2013-02-11 |
US8338414B2 (en) | 2012-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006095906A1 (ja) | 複素環式化合物を有効成分とする免疫抑制剤及び抗腫瘍剤 | |
CN107873032B (zh) | 苯并氧氮杂*噁唑烷酮化合物及其使用方法 | |
CN107995911B (zh) | 苯并氧氮杂*噁唑烷酮化合物及其使用方法 | |
KR20230173083A (ko) | Cdk 억제제 및 이의 사용 방법 | |
US20160046638A1 (en) | Certain protein kinase inhibitors | |
CA2863517C (en) | Substituted pyrimidine compounds and their use as syk inhibitors | |
US11440923B2 (en) | Substituted macrocyclic indole derivatives | |
BR112015006019B1 (pt) | composto e uso de um composto | |
US11401278B2 (en) | Macrocyclic indole derivatives | |
EA029017B1 (ru) | ДВОЙНЫЕ СЕЛЕКТИВНЫЕ ИНГИБИТОРЫ PI3-КИНАЗ δ И γ | |
US20230150949A1 (en) | Novel barbituric acid derivatives, their preparation and use thereof as leukocyte transmigration inhibitors and for treating inflammatory diseases, autoimmune diseases and cancer | |
WO2017025493A1 (en) | Quinoline ezh2 inhibitors | |
JP6554480B2 (ja) | オキセパン−2−イル−ピラゾール−4−イル−ヘテロシクリル−カルボキサミド化合物と使用方法 | |
WO2022226052A1 (en) | Pi3k inhibitors, nanoformulations, and uses thereof | |
CN118696046A (zh) | 作为kras抑制剂的稠合嘧啶 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680007888.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2599879 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006221285 Country of ref document: AU Ref document number: 3220/KOLNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007507227 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006221285 Country of ref document: AU Date of ref document: 20060313 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006221285 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007137651 Country of ref document: RU Ref document number: 2006729002 Country of ref document: EP Ref document number: 1020077023354 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2006729002 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11847593 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0608291 Country of ref document: BR Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020137016829 Country of ref document: KR |